Kaiser, M.Dimopoulos, M.A.Gay, F.Schjesvold, F.H.Beksac, M.Hajek, R.Weisel, K.C.Goldschmidt, H.Maisnar, V.Moreau, P.Min, C.-.Pluta, A.Chng, W.J.Zweegman, S.Mateos, M.-.Spencer, A.Iida, S.Morgan, G.J.Suryanarayan, K.Teng, Z.Skacel, T.Palumbo, A.Dash, A.B.Gupta, N.Labotka, R.Rajkumar, S.V.Grp, T.O.
(2019). Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial,
BRITISH JOURNAL OF HAEMATOLOGY,
Vol.185,
pp.18-19.
Verkleij, C.Broekmans, M.van Duin, M.Frerichs, K.Kuiper, R.Kaiser, M.Morgan, G.Axel, A.Chiu, C.Sonneveld, P.Zweegman, S.Adams, H.Mutis, T.Van de Donk, N.
(2019). Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma,
Clinical Lymphoma Myeloma and Leukemia,
Vol.19
(10),
pp.e122-e123.
Kaiser, M.Beksac, M.Gulbrandsen, N.Schjesvold, F.Hajek, R.Moreau, P.de Arriba, F.Mateos, M.-.West, S.Spencer, A.Rajkumar, S.V.Suryanarayan, K.Czorniak, M.Teng, Z.Labotka, R.Dimopoulos, M.A.
(2019). Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM),
Clinical Lymphoma Myeloma and Leukemia,
Vol.19
(10),
p.e293.
Bird, S.Sriskandarajah, P.Kaiser, M.Pawlyn, C.Boyd, K.
(2019). A ‘real-world’ study of panobinostat, bortezomib and dexamethasone in a very heavily pre-treated population of myeloma patients,
Clinical Lymphoma Myeloma and Leukemia,
Vol.19
(10),
pp.e244-e245.
Mateos, M.-.Nahi, H.Legiec, W.Grosicki, S.Vorobyev, V.Spicka, I.Hungria, V.T.Korenkova, S.Bahlis, N.J.Flogegard, M.Blade, J.Moreau, P.Kaiser, M.Iida, S.Laubach, J.Ahmadi, T.Parasrampuria, D.A.Peng, L.Qi, M.Usmani, S.Z.
(2019). Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.,
JOURNAL OF CLINICAL ONCOLOGY,
Vol.37
(15).
Sriskandarajah, P.Ahmed, N.Burd, C.Shah, V.Riddell, A.Boyd, K.Kaiser, M.Messiou, C.
(2018). Detection of asymptomatic femoral head avascular necrosis on routine whole body MRI in patients with multiple myeloma provides opportunities for joint preservation,
BRITISH JOURNAL OF HAEMATOLOGY,
Vol.181,
p.98.
Austin, M.O'Connor, S.Morilla, R.Kaiser, M.Boyd, K.
(2018). False Negative Rate of Minimal Residual Disease Measurement by Multiparameter Flow Cytometry in Multiple Myeloma when Compared to Trephine Immunohistochemistry,
Clinical Lymphoma Myeloma and Leukemia,
Vol.18,
pp.S243-S244.
Sriskandarajah, P.Macleod, K.Carragher, N.Kaiser, M.F.Whittaker, S.R.
(2018). Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis,
Annals of Oncology,
Vol.29,
p.viii7.
Croft, J.Hall, A.Walker, K.Sherborne, A.L.Boyd, K.Garg, M.Pawlyn, C.Sherratt, D.Reed, S.Pierceall, W.E.Cook, G.Thakurta, A.Brown, S.R.Kaiser, M.
(2018). Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone,
Blood,
Vol.132
(Supplement 1),
p.4482.
Pawlyn, C.Jackson, G.H.Cairns, D.Striha, A.Hockaday, A.Jacques, G.Jones, J.R.Boyd, K.Kishore, B.Garg, M.Williams, C.Karunanithi, K.Lindsay, J.Jenner, M.Cook, G.Russell, N.H.Kaiser, M.Drayson, M.T.Owen, R.G.Gregory, W.M.Morgan, G.Davies, F.E.
(2018). Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial,
Blood,
Vol.132
(Supplement 1),
p.3280.
Shah, V.Johnson, D.C.Sherborne, A.L.Ellis, S.Price, A.Kendall, J.Chiecchio, L.Striha, A.Hockaday, A.Pawlyn, C.Jenner, M.Drayson, M.T.Owen, R.G.Gregory, W.M.Morgan, G.Davies, F.E.Houlston, R.S.Cook, G.Cairns, D.Jackson, G.H.Kaiser, M.
(2018). Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials,
Blood,
Vol.132
(Supplement 1),
p.2000.
Bygrave, C.A.Pawlyn, C.Davies, F.E.Cairns, D.Striha, A.Hockaday, A.Paterson, A.Jones, J.R.Kishore, B.Garg, M.Williams, C.Karunanithi, K.Lindsay, J.Jenner, M.W.Cook, G.Drayson, M.T.Owen, R.G.Russel, N.H.Gregory, W.M.Morgan, G.J.Jackson, G.Kaiser, M.
(2018). Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial,
Blood,
Vol.132
(Supplement 1),
p.122.
Jackson, G.H.Davies, F.E.Pawlyn, C.Cairns, D.Striha, A.Hockaday, A.Collett, C.Jones, J.R.Kishore, B.Garg, M.Williams, C.Karunanithi, K.Lindsay, J.Jenner, M.Cook, G.Russell, N.H.Kaiser, M.Drayson, M.T.Owen, R.G.Gregory, W.M.Morgan, G.
(2018). A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study,
Blood,
Vol.132
(Supplement 1),
p.302.
Jackson, G.H.Davies, F.E.Pawlyn, C.Cairns, D.A.Striha, A.Collett, C.Waterhouse, A.Jones, J.R.Kishore, B.Garg, M.Williams, C.D.Karunanithi, K.Lindsay, J.Jenner, M.W.Cook, G.Kaiser, M.F.Drayson, M.T.Owen, R.G.Russell, N.H.Gregory, W.M.Morgan, G.J.
(2016). Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study,
Blood,
Vol.128
(22),
p.1143.
Popat, R.Brown, S.R.Tillotson, A.-.Collinson, F.Flanagan, L.M.Williams, C.D.Yong, K.L.Cook, G.Jenner, M.W.Kaiser, M.Cavet, J.El-Sharkawi, D.Ng, C.-.Low, E.Morgan, G.J.Davies, F.E.
(2016). A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial,
Blood,
Vol.128
(22),
p.3321.
de Tute, R.M.Rawstron, A.C.Cairns, D.A.Pawlyn, C.Davies, F.E.Collett, C.Kaiser, M.F.Jones, J.R.Waterhouse, A.Striha, A.Cook, G.Jenner, M.W.Russell, N.H.Drayson, M.T.Gregory, W.M.Jackson, G.H.Morgan, G.J.Owen, R.G.
(2016). Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial,
Blood,
Vol.128
(22),
p.245.
Pawlyn, C.Kaiser, M.F.Stein, C.K.Wardell, C.P.Macleod, V.Edmondson, R.Barlogie, B.Walker, B.Morgan, G.J.Davies, F.E.
(2015). Abstract 3516: EZH2 overexpression in myeloma patients shortens survival and in-vitro data supports a potential new targeted treatment strategy,
Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Experimental and Molecular Therapeutics, .
Raje, N.Chau, I.Hyman, D.M.Ribrag, V.Blay, J.-.Tabernero, J.Elena Elez-Fernandez, M.Wolf, J.S.Sirzen, F.Yee, A.Faris, J.Kaiser, M.Landau, H.Michot, J.-.Veronese, L.Makrutzki, M.Lasserre, S.F.Puzanov, I.Baselga, J.
(2015). Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF(V600) Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study,
BLOOD,
Vol.126
(23).
Pawlyn, C.Chambers, T.Macleod, V.Sappington, D.Buros, A.Stein, C.K.Kaiser, M.F.Burke, R.Hoelder, S.Boysen, G.Edmondson, R.D.Morgan, G.J.Davies, F.E.
(2015). Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines,
BLOOD,
Vol.126
(23).
Jones, J.R.Cairns, D.A.Sigsworth, R.Collett, C.Pawlyn, C.Striha, A.Melchor, L.Kaiser, M.F.Drayson, M.T.Davies, F.E.Gregory, W.M.Boyd, K.Owen, R.G.Jackson, G.H.Morgan, G.J.
(2015). Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases,
BLOOD,
Vol.126
(23).
Stein, C.K.Davies, F.E.Heuck, C.Weinhold, N.Chavan, S.S.Walker, B.A.Thanendrarajan, S.Epstein, J.Yaccoby, S.Zangari, M.van Rhee, F.Kaiser, M.F.Jackson, G.H.Sonneveld, P.Goldschmidt, H.Bergsagel, P.L.Barlogie, B.Morgan, G.J.
(2015). Molecular Subtyping and Risk Stratification for the Classification of Myeloma,
BLOOD,
Vol.126
(23).
Tornatore, L.Acton, G.Adams, N.Campbell, E.A.Kelly, J.Szydlo, R.M.Tarbit, M.Bannoo, S.D'Andrea, D.Capece, D.Sandomenico, A.Dyson, J.Leonardi, A.Driessen, C.Ruvo, M.Anees, I.Oblak, M.Quaid, S.Al-Obaidi, M.J.Auner, H.Benbenjamin, R.Kaczmarski, R.S.Kaiser, M.F.Mehta, A.Oakervee, H.E.Schey, S.A.Wechalekar, A.Apperley, J.F.Franzoso, G.
(2015). Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3,
Blood,
Vol.126
(23),
p.868.
Yong, K.L.Brown, S.Hinsley, S.Flanagan, L.Rabin, N.Ramasamy, K.Cavenagh, J.Owen, R.G.Kaiser, M.F.Low, E.Williams, C.
(2015). Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen,
BLOOD,
Vol.126
(23).
Pawlyn, C.Davies, F.E.Cairns, D.A.Collett, C.Chalmers, A.Striha, A.Jones, J.R.Garg, M.Allotey, D.Karunanithi, K.Milligan, D.Kaiser, M.F.Jenner, M.W.Cook, G.Russell, N.H.Drayson, M.T.Owen, R.G.Gregory, W.M.Jackson, G.H.Morgan, G.J.
(2015). Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients,
BLOOD,
Vol.126
(23).
Pawlyn, C.Kaiser, M.F.Fowkes, L.Jones, J.R.Davies, F.E.Morgan, G.J.Collins, D.Sharma, B.Riddell, A.Messiou, C.
(2015). WB-DWI MRI Scanning Outperforms FDG PET-CT for the Assessment of Myeloma Disease Burden,
BLOOD,
Vol.126
(23).
Sriskandarajah, P.Pawlyn, C.Boyle, E.Mohammed, K.Ethell, M.Potter, M.N.Dearden, C.Davies, F.E.Morgan, G.J.Kaiser, M.F.
(2015). Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience,
BRITISH JOURNAL OF HAEMATOLOGY,
Vol.169,
pp.64-65.
Pawlyn, C.Davies, F.Cairns, D.Collett, C.Jones, J.Kaiser, M.Chalmers, A.Striha, A.Milligan, D.Lindsay, J.Chapman, C.Allotey, D.Shafeek, S.Karunanithi, K.Cook, G.Russell, N.Drayson, M.Owen, R.Gregory, W.Jackson, G.Morgan, G.
(2015). THE QUADRUPLET COMBINATION OF CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS,
HAEMATOLOGICA,
Vol.100,
p.152.
Wale, A.Pawlyn, C.Kaiser, M.Messiou, C.
(2015). WHOLE BODY DIFFUSION WEIGHTED MRI SCANNING IN PATIENTS WITH MYELOMA. INCIDENTAL FINDINGS-THE ROYAL MARSDEN EXPERIENCE,
HAEMATOLOGICA,
Vol.100,
p.88.
Palumbo, A.Moreau, P.Dimopoulos, M.A.Corradini, P.Cavo, M.Delforge, M.Weisel, K.C.Goldschmidt, H.Petrini, M.Kaiser, M.F.Slaughter, A.Simcock, M.Herring, J.Peluso, T.Sternas, L.Zaki, M.Ocio, E.M.
(2015). OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY,
HAEMATOLOGICA,
Vol.100,
pp.82-83.
Lonial, S.Delforge, M.Einsele, H.Moreau, P.Kaiser, M.Dimopoulos, M.A.Oriol, A.Gyger, M.Hilder, B.Ptaszynski, A.M.Aitchison, R.Orlowski, R.Z.
(2015). The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.,
JOURNAL OF CLINICAL ONCOLOGY,
Vol.33
(15).
Melchor, L.Jones, J.R.Lenive, O.Peterson, E.A.Brioli, A.Murison, A.Wardell, C.P.Kaiser, M.F.Proszek, P.Boyle, E.M.others,
(2015). Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing,
Blood,
Vol.126,
p.371.
Kaiser, M.F.Boyle, E.M.Walker, B.A.Proszek, P.Johnson, D.C.Pawlyn, C.Jones, J.R.Savola, S.Owen, R.G.Drayson, M.T.others,
(2015). Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases,
Blood,
Vol.126,
p.2981.
Kaiser, M.F.Boyle, E.M.Walker, B.A.Proszek, P.Johnson, D.C.Pawlyn, C.Jones, J.R.Savola, S.Owen, R.G.Drayson, M.T.others,
(2015). Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance-an Analysis of 1,036 Myeloma Trial Patients,
Blood,
Vol.126,
p.2983.
Pawlyn, C.Khan, M.S.Davies, F.E.Sriskandarajah, P.Kaiser, M.Andreyev, J.Morgan, G.J.
(2014). TREATMENT WITH THE BILE-ACID SEQUESTRANT COLESEVELAM IMPROVES LENALIDOMIDE ASSOCIATED DIARRHOEA IN MYELOMA PATIENTS,
HAEMATOLOGICA,
Vol.99,
p.382.
Boyle, E.M.Walker, B.A.Wardell, C.P.Murison, A.Melchor, L.Kaiser, M.F.Proszek, P.Dahir, N.Johnson, D.C.Pawlyn, C.others,
(2014). Mutational patterns and copy number changes at diagnosis are a powerful tool to predict outcome: result of the sequencing study of 463 newly diagnosed myeloma trial patients,
Blood,
Vol.124,
p.637.
Kaiser, M.F.Boyle, E.M.Walker, B.A.Pawlyn, C.Proszek, P.Dahir, N.Johnson, D.C.Savola, S.Cairns, D.A.Gregory, W.others,
(2014). High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients,
Blood,
Vol.124,
p.172.
Kaiser, M.F.Murison, A.Pawlyn, C.Boyle, E.M.Johnson, D.C.Walker, B.A.Wu, P.Dahir, N.Wardell, C.P.Proszek, P.others,
(2014). High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation,
Blood,
Vol.124,
p.2189.
Kaiser, M.F.Proszek, P.Dahir, N.Walker, B.A.Savola, S.Boyle, E.M.Johnson, D.C.Cairns, D.A.Gregory, W.Jackson, G.others,
(2014). Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA,
Blood,
Vol.124,
p.5168.
Pawlyn, C.Kaiser, M.F.Walker, B.A.Wardell, C.P.Murison, A.Johnson, D.C.Melchor, L.Boyle, E.M.Jones, J.Dahir, N.others,
(2014). The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact,
Blood,
Vol.124,
p.2194.
Melchor, L.Murison, A.Boyle, E.M.Wardell, C.P.Jones, J.Kaiser, M.F.Pawlyn, C.Johnson, D.C.Proszek, P.Dahir, N.others,
(2014). The extent of intra-clonal genetic diversity within the myeloma clone is a predictive biomarker of progression and outcome after treatment,
Blood,
Vol.124,
p.640.
Pawlyn, C.Melchor, L.Boyle, E.M.Brioli, A.Kaiser, M.F.Gregory, W.Drayson, M.T.Jackson, G.Ross, F.M.Child, J.A.Morgan, G.J.Davies, F.E.
(2013). Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma,
Blood,
Vol.122
(21),
p.529.
Kaiser, M.F.Begum, D.Proszek, P.Dahir, N.Gonzalez de Castro, D.Pawlyn, C.Brioli, A.Savola, S.Gregory, W.Owen, R.G.Jackson, G.H.Davies, F.E.Walker, B.A.Morgan, G.J.
(2013). A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort,
Blood,
Vol.122
(21),
p.3097.
Brioli, A.Campbell, J.P.Kaiser, M.F.Pawlyn, C.Jackson, G.H.Gregory, W.Owen, R.G.Child, J.A.Davies, F.E.Cavo, M.Drayson, M.T.Morgan, G.J.
(2013). Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity,
Blood,
Vol.122
(21),
p.752.
Murison, A.Wardell, C.P.Johnson, D.C.Pawlyn, C.Mirabella, F.Melchor, L.Fenwick, K.Kozarewa, I.Davies, F.E.Walker, B.A.others,
(2013). Discovery of genome wide epigenetic programming in t (4; 14) multiple myeloma and in the progression from myeloma to plasma cell leukemia via methyl binding domain protein capture and sequencing,
Blood,
Vol.122,
p.599.
Wu, P.Agnelli, L.Walker, B.A.Todoerti, K.Johnson, D.C.Kaiser, M.Wardell, C.P.Gregory, W.M.Davies, F.E.Brewer, D.Neri, A.Morgan, G.J.
(2012). Improved Risk Stratification in Myeloma Using Microrna-Based Classifier,
BLOOD,
Vol.120
(21).
Kaiser, M.F.Walker, B.A.Wardell, C.P.Mirabella, F.Fryer, R.A.Johnson, D.C.Fenwick, K.Kozarewa, I.Davies, F.E.Morgan, G.J.
(2012). High-Resolution, Genome Wide Analysis of DNA Methylation Provides Insights Into the Epigenetic Architecture of t(4;14) Myeloma,
BLOOD,
Vol.120
(21).
Kaiser, M.F.Johnson, D.C.Walker, B.A.Wu, P.Wardell, C.P.Davies, F.E.Morgan, G.J.
(2012). Genome-Wide Methylation and Gene Expression Analyses Identify Patients At High and Low Risk of Disease Progression,
BLOOD,
Vol.120
(21).
Brioli, A.Ross, F.M.Kaiser, M.F.Pawlyn, C.Wu, P.Gregory, W.M.Owen, R.G.Jackson, G.H.Cavo, M.Davies, F.E.Morgan, G.J.
(2012). The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping,
BLOOD,
Vol.120
(21).
Kaiser, M.F.Heider, U.Mieth, M.Zustin, J.Kuehnl, A.von Metzler, I.Sezer, O.
(2012). Induction of CXCL1 in Osteoblasts by Myeloma Cells Promotes Migration of Osteoclast Precursors,
BLOOD,
Vol.120
(21).
Wu, P.Agnelli, L.Walker, B.A.Todoerti, K.Johnson, D.C.Kaiser, M.Wardell, C.P.Gregory, W.M.Davies, F.E.Brewer, D.Neri, A.Morgan, G.J.
(2012). Improved Risk Stratification in Myeloma Using Microrna-Based Classifier,
BLOOD,
Vol.120
(21).
Kaiser, M.F.Johnson, D.C.Walker, B.A.Wu, P.Wardell, C.P.Davies, F.E.Morgan, G.J.
(2012). Genome-Wide Methylation and Gene Expression Analyses Identify Patients At High and Low Risk of Disease Progression,
BLOOD,
Vol.120
(21).
Kaiser, M.Kuehnl, A.Ortiz-Tanchez, J.Schlee, C.Mochmann, L.H.Heesch, S.Thiel, E.Baldus, C.D.
(2011). The HSP70 inhibitor Pifithrin-mu is highly active against myeloid and lymphoid leukemic cells,
ONKOLOGIE,
Vol.34,
p.76.
Kuehnl, A.Kaiser, M.Heesch, S.Thiel, E.Baldus, C.
(2010). High expression of IGFBP2 in adult acute myeloid leukemia and association with drug resistance,
ONKOLOGIE,
Vol.33,
pp.215-216.
Heider, U.Kaiser, M.Mieth, M.von Metzler, I.Sezer, O.
(2010). The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of mesenchymal stem cells via upregulation of vitamin D receptor signaling: Implications for multiple myeloma,
ONKOLOGIE,
Vol.33,
p.186.
Kaiser, M.Kuehnl, A.Ortiz-Tanchez, J.Benlasfer, O.Schlee, C.Heesch, S.Thiel, E.Baldus, C.
(2010). Antileukemic Activity of the HSP70 Inhibitor Pifithrin-mu,
BLOOD,
Vol.116
(21),
pp.1354-1355.
Jakob, C.Sterz, J.Mieth, M.Heider, U.Kaiser, M.Liebisch, P.Rademacher, J.Mueller, C.Sezer, O.
(2009). The Bone Marker ICTP Adds to the Prognostic Significance of the ISS in Symptomatic Multiple Myeloma,
CLINICAL LYMPHOMA & MYELOMA,
Vol.9,
pp.S54-S55.
Kaiser, M.Lamottke, B.Jensen, M.R.Quadt, C.Garcia-Echeverria, C.Mieth, M.Heider, U.Sezer, O.
(2009). Synergistic Action of Heat-Shock Protein-90 Inhibitor NVP-AUY922 with Histone Deacetylase Inhibition,
CLINICAL LYMPHOMA & MYELOMA,
Vol.9,
p.S129.
Goerke, A.Jakob, C.Sterz, J.Heider, U.Kaiser, M.Mieth, M.Mueller, C.Terpos, E.Sezer, O.
(2009). SERUM LEVELS OF TOTAL-RANKL IN MULTIPLE MYELOMA,
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL,
Vol.94,
pp.161-162.
Heider, U.Kaiser, M.Mieth, M.Rademacher, J.Lamottke, B.Jakob, C.Braendle, E.Stover, D.Sezer, O.
(2009). SERUM DKK1 IN MULTIPLE MYELOMA PATIENTS,
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL,
Vol.94,
p.159.
Jakob, C.Sterz, J.Liebisch, P.Heider, U.Kaiser, M.Mieth, M.Mueller, C.Sezer, O.
(2009). INCORPORATION OF THE BONE MARKER CARBOXY-TERMINAL TELOPEPTIDE OF TYPE-1 COLLAGEN (ICTP) INTO A COMBINED ISS-ICTP SCORE IMPROVES THE PROGNOSTIC SIGNIFICANCE OF THE ISS IN SYMPTOMATIC MULTIPLE MYELOMA,
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL,
Vol.94,
p.384.
Goerke, A.Jakob, C.Sterz, J.Heider, U.Kaiser, M.Mieth, M.Mueller, C.Terpos, E.Sezer, O.
(2009). SERUM LEVELS OF TOTAL-RANKL IN MULTIPLE MYELOMA,
HAEMATOLOGICA,
Vol.94,
pp.161-162.
Heider, U.Kaiser, M.Mieth, M.Rademacher, J.Lamottke, B.Jakob, C.Braendle, E.Stover, D.Sezer, O.
(2009). SERUM DKK1 IN MULTIPLE MYELOMA PATIENTS,
HAEMATOLOGICA,
Vol.94,
p.159.
Jakob, C.Sterz, J.Liebisch, P.Heider, U.Kaiser, M.Mieth, M.Mueller, C.Sezer, O.
(2009). INCORPORATION OF THE BONE MARKER CARBOXY-TERMINAL TELOPEPTIDE OF TYPE-1 COLLAGEN (ICTP) INTO A COMBINED ISS-ICTP SCORE IMPROVES THE PROGNOSTIC SIGNIFICANCE OF THE ISS IN SYMPTOMATIC MULTIPLE MYELOMA,
HAEMATOLOGICA,
Vol.94,
p.384.
Heider, U.Rademacher, J.Kaiser, M.von Metzler, I.Marquardt, K.Sezer, O.
(2009). Decrease in CD4+T Cells in Multiple Myeloma Patients Receiving Bortezomib,
BLOOD,
Vol.114
(22),
p.1487.
Jakob, C.Wernecke, T.Sterz, J.Goerke, A.Heider, U.Kaiser, M.Mieth, M.Ziefle, S.Sezer, O.
(2009). An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.,
BLOOD,
Vol.114
(22),
p.1096.
Jakob, C.Sterz, J.von Metzler, I.Kuckelkorn, U.Braun, H.A.Kaiser, M.Heider, U.Rademacher, J.Kleeberg, L.Kloetzel, P.M.Sezer, O.
(2008). Bsc2118, a novel proteasome inhibitor, causes growth inhibition, cell cycle arrest and cyclin D1 degradation in mantle cell lymphoma (MCL) cell lines,
ANNALS OF ONCOLOGY,
Vol.19,
p.175.
Sezer, O.Kaiser, M.Siegel, D.Prosser, I.Mateos, M.V.Kangas, M.Jalaluddin, M.Bourquelot, P.Blade, J.Miguel, J.S.Anderson, K.Bradner, J.
(2008). A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN ADULT PATIENTS WITH MULTIPLE MYELOMA (MM),
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL,
Vol.93,
p.176.
Jakob, C.Liebisch, P.Heider, U.Kaiser, M.Sterz, J.Rademacher, J.Fleissner, C.Mueller, C.Sezer, O.
(2008). Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy.,
BLOOD,
Vol.112
(11),
p.940.
Sezer, O.Kaiser, M.Siegel, D.Prosser, I.Mateos, M.V.Kangas, M.Jalaluddin, M.Bourquelot, P.Blade, J.San Miguel, J.Anderson, K.Bradner, J.
(2008). A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN ADULT PATIENTS WITH MULTIPLE MYELOMA (MM),
HAEMATOLOGICA,
Vol.93,
p.176.
Sterz, J.Metzler, I.V.Kuckelkorn, U.Braun, H.A.Rotzer, S.Kaiser, M.Fleissner, C.Heider, U.Kloetzel, P.M.Sezer, O.Jakob, C.
(2007). BSC2118, a novel proteasome inhibitor with in vitro anti-tumor activity in multiple myeloma,
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL,
Vol.92
(6),
p.152.
Jakob, C.Egerer, K.Liebisch, P.Kuckelkorn, U.Turkmen, S.Kaiser, M.Fleissner, C.Sterz, J.Heider, U.Kleeberg, L.Feist, E.Burmester, G.R.Kloetzel, P.M.Sezer, O.
(2007). Circulating proteasome levels in multiple myeloma,
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL,
Vol.92
(6),
p.119.
Jakob, C.Liebisch, P.Egerer, K.Sterz, J.Kaiser, M.Roetzer, S.Heider, U.Rademacher, J.Fleissner, C.Kloetzel, P.M.Terpos, E.Sezer, O.
(2007). The bone resorption marker serum-ICTP and the circulating proteasome levels separate ISS-Stages 1-3 and are the most powerful prognostic factors, for overall survival in newly diagnosed symptomatic multiple myeloma,
BLOOD,
Vol.110
(11),
pp.441A-442A.
Jakob, C.Sterz, J.von Metzler, I.Kuckelkom, U.Braun, H.A.Roetzer, S.Kaiser, M.Heider, U.Rademacher, J.Kloetzel, P.M.Sezer, O.
(2007). The proteasome inhibitor BSc2118 causes growth inhibition, cell cycle arrest and cyclin D1 degradation in mantle cell lymphoma cell lines,
BLOOD,
Vol.110
(11),
p.420A.
Sterz, J.Jakob, C.Kuckelkorn, U.Braun, H.A.Kaiser, M.Fleissner, C.Kleeberg, L.Heider, U.Possinger, K.Kloetzel, P.M.Sezer, O.Zavrski, I.
(2006). BSc2118, a novel proteasome inhibitor, shows anti-tumor activity in multiple myeloma and mantle cell lymphoma.,
BLOOD,
Vol.108
(11),
p.991A.
Heider, U.Kaiser, M.Zavrski, I.Sterz, J.Jakob, C.Fleissner, C.Hecht, M.Kleeberg, L.Braun, C.Possinger, K.Sezer, O.
(2006). Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.,
BLOOD,
Vol.108
(11),
pp.710A-711A.
Zavrski, I.Hecht, M.Krebbel, H.Fleissner, C.Mieth, M.Kaiser, M.Heider, U.Jakob, C.Sterz, J.Possinger, K.Sezer, O.
(2006). Bortezomib inhibits human osteoclastogenesis.,
BLOOD,
Vol.108
(11),
p.406A.
Rosche, M.Zavrski, I.Schmid, P.Kaiser, M.Elsmer, E.Possinger, K.Sezer, O.
(2006). Combined proteasome and histone deacetylase inhibition in breast cancer cell lines.,
BREAST CANCER RESEARCH AND TREATMENT,
Vol.100,
p.S71.
Zavrski, I.Kaiser, M.Rosche, M.Heider, U.Jakob, C.Fleissner, C.Possinger, K.Sezer, O.
(2005). Bortezomib (PS-341) sensitizes multiple myeloma cell lines to etoposide-induced apoptosis.,
BLOOD,
Vol.106
(11),
p.375B.
Jakob, C.Sterz, J.Kleeberg, L.Zavrski, L.Kaiser, M.Eucker, J.Heider, U.Possinger, K.Sezer, O.
(2005). Serum total-RANKL is elevated in patients with multiple myeloma, increases with ISS stage and decreases after induction therapy.,
BLOOD,
Vol.106
(11),
p.705A.
Kaiser, M.Heider, U.Zavrski, I.Sterz, J.Possinger, K.Sezer, O.
(2005). Valproic acid inihibts histone deacetylases and proliferation and induces cell cycle arrest and apoptosis in multiple myeloma.,
BLOOD,
Vol.106
(11),
p.374B.
Heider, U.Kaiser, M.Zavrski, I.Sterz, J.Jakob, C.Fleissner, C.Possinger, K.Sezer, O.
(2005). Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in mantle cell lymphoma and reduce VEGF production,
BLOOD,
Vol.106
(11),
p.284B.
Heider, U.Kaiser, M.Muller, C.Schulz, C.O.Jakob, C.Zavrski, I.Eucker, J.Sterz, J.Kleeberg, L.Possinger, K.Sezer, O.
(2005). Treatment of bortezomib increases osteoblast function in patients with multiple myeloma.,
BLOOD,
Vol.106
(11),
p.965A.